MEDICATION-ASSISTED TREATMENT CENTERS OF EXCELLENCE

November 5, 2021 **BIWEEKLY NEWSLETTER** Vol. 35

OBAT News: Any Licensed Health Care Professional Can Now Function as a Patient Navigator in the OBAT Model

As per the NJ-21-0007 approval, any licensed health care professional can now function as a patient navigator in the OBAT model. This includes, but is not limited to, prescribers such as physicians, APNs, and PAs. This provider, however, cannot serve both the prescriber and the navigator role simultaneously. Therefore, if a group practice has more than one prescriber, such as two APNs, one APN can function as the prescriber and the other as the navigator. If you have any questions, please contact coe@njms.rutgers.edu

Click to be one of the first to see the NJ MAT COE OBAT Evidence-Based Manual for Primary Care and Specialty Practices

New Federal Strategy Focusing on the Needs of People with Addiction to Combat Overdoses

The Biden administration is rolling out a new coordinated strategy that it hopes will slow the increasing rise in drug overdose deaths. According to the CDC, roughly 100,000 deaths have occurred from overdoses over a 12-month period, which is a massive surge from the year prior. The federal government will now directly support ideas known broadly as harm reduction. That means providing direct support and care to people actively using illegal drugs such as syringe exchange programs, providing fentanyl test strips, and creation of safe consumption sites. Drug policy experts say that this set of ideas could begin to change the federal government's role in tackling the addiction crisis—treating people who use drugs not as criminals, but as patients needing care.

CLICK TO READ THE NPR NEWS ARTICLE

WHAT'S INSIDE

UPCOMING EVENTS

11/12: Project ECHO: Case-Based Application of Homelessness & OUD

12/1: MAT Lunch Hour: ED Buprenorphine Induction

12/2: OBAT Skills Lab

12/8: OBAT Support Event

HEADLINES

ASAM Statement on MOUD with Methadone

"B-Team" to Treat Hospitalized Patients with OUD

Harm Reduction for Patients with Severe Injection-Related Infections

Geographic Accessibility of MOUD from 2014 to 2020

RESOURCES

NJ MAT COE OBAT Manual

Buprenorphine Micro-Induction Patient Health Communication

Medication Infographic

Upcoming Events

Next Project ECHO: Case-Based Application: Frequent Health Care Utilization with Patients Experiencing Homelessness

If you missed any of the previous MAT or continuous quality improvement ECHO sessions, they are posted within the Northern COE Website webinar archive. Please note that you can only receive CE credits by attending live ECHO sessions.

This ECHO session will be a follow-up to our didactic ECHO topic of Addressing Homelessness in the Patient with OUD. Lynda Bascelli, MD, of Cooper University Health Care, will lead the discussion on additional cases of patients with housing instability and frequent health care utilization.

This session takes place on
Friday, November 12 from 12:00 – 1:00 PM

Save the Date: *The next Project ECHO on Addressing Legal Issues in Patients with OUD will be on Friday, December 3 from 12:00 – 1:00 PM*

Do you have a patient or client you would like to present to the panel to receive recommendations and suggestions for management? Please click **here** to email your question(s) or scenario(s).

REGISTER HERE

OBAT Navigator Skills Lab: Trauma-Informed Care

This skills lab will help participants:
1.) Explain the importance of understanding trauma
2.) Identify patient behaviors as symptoms of previous experiences and potential traumas
3.) Understand the role of self-care and team-based care to supporting trauma-informed practice

Join us for the next training on Thursday, December 2 from 12:00 – 1:00 PM

REGISTER HERE



MAT Lunch Hour: ED Buprenorphine Induction

Join the NJ MAT COEs and the Camden Coalition of Healthcare Providers for the next MAT Lunch Hour to network, collaborate, and discuss. During the event, we will discuss the role of buprenorphine induction in the ED.

The ED setting presents an ideal opportunity to start patients on evidence-based, mortality-reducing buprenorphine treatment for opioid use disorder. Rachel Haroz, MD, FAACT, Division Head of Toxicology & Addiction Medicine at Cooper University Health Care and Community Partnership Director for the Southern NJ MAT Center of Excellence, will lead the discussion. Prescriber education and patient health communication resources will also be provided.

Next Forum: Wednesday, December 1 from 12:00 – 1:00 PM

REGISTER HERE

OBAT Navigator Support Event

These events are an ongoing opportunity for OBAT navigators and other SUD navigators/case managers to continue learning through:

Discussion of (de-identified) patient cases and how to support thinking through patient engagement strategies, potential resources, and how to practice self-care while doing this work; presentations and updated resources about relevant topics such as harm reduction, strategies for identifying new community resources, and telephonic engagement during the COVID-19 pandemic

This event will take place on Wednesday, December 8 from 1:00 – 2:00 PM

REGISTER HERE

Recent Literature

ASAM Issues Public Policy Statement on the Regulation of the Treatment of Opioid Use Disorder with Methadone



Despite the history and evidence supporting the effectiveness of methadone for the treatment of OUD, regulatory barriers and stigma continue to make this lifesaving treatment largely inaccessible. In response, ASAM recently issued a Public Policy Statement on the Regulation of the Treatment of Opioid Use Disorder with Methadone, highlighting 20 policy recommendations that align with current evidence-based practices to improve both access to and the quality of methadone treatment. For several of the key recommendations, click below to view the policy statement.

CLICK TO READ THE ARTICLE

The Development & Implementation of a "B-Team" (Buprenorphine Team) to Treat Hospitalized Patients with OUD

Hospitalization of a patient with opioid use disorder presents a major opportunity to initiate patients on MOUD they otherwise would not receive. Literature has shown that this intervention increases the chances that patients follow-up in outpatient treatment, have higher treatment retention, and have reduced illicit opioid use, which altogether may reduce the risk of overdose and deaths. Initiating pharmacotherapy for interested patients with OUD during hospitalization has been made easier due to changes in the HHS guidelines allowing prescribers to treat up to 30 patients without a waiver. Initiation of buprenorphine also does not require a formal addiction consultation service and can be accomplished by any in-hospital prescriber with the support of a multidisciplinary team and senior leadership. Continued barriers to widespread adoption still exist and working collaboratively to address these will ensure that implementation is successful.

For more information on this "B-team" developed in an academic medical center in Texas, click below.

If you need help with implementing prescribing of MOUD in your health system or practice, please contact your respective NJ MAT Center of Excellence.


CLICK TO READ THE ARTICLE

Recent Literature (cont.)

Harm Reduction for the Treatment of Patients with Severe Injection-Related Infections: Description of the Jackson SIRI Team

Hospitalizations for severe injection-related infections (SIRI) due to IV drug use are increasingly more common. People who inject drugs (PWID) experiencing SIRIs often do not receive the treatment needed to reduce these harms, thereby increasing hospital length of stay, chances of leaving against medical advice, and increasing morbidity and mortality. The purpose of this study was to describe the development of an integrated "SIRI Team" and its initial barriers and facilitators to success. Over 8 months, this team saw 21 patients with OUD with 20 surviving through discharge. At 90-days post discharge, only 25% were re-admitted while 70% reported taking their MOUD and 95% of the patients continued taking their antibiotic course. Innovative models of a "SIRI team" that integrate both SUD and infectious disease care for the treatment of SIRIs can improve patient outcomes in those with SIRI.

CLICK TO READ THE ARTICLE



Population-Based Estimates of Geographic Accessibility of Medication for Opioid Use Disorder by Substance Use Disorder Treatment Facilities from 2014 to 2020

Using Data from the National Directory of Drug and Alcohol Abuse Treatment, this study sought to understand the geographic accessibility to a SUD treatment facility offering MOUD, which can inform our efforts to address the ongoing opioid epidemic. Counties with a treatment facility offering one type of MOUD as a form of treatment increased from 30% to 45% from 2014 to 2020 while those with facilities offering all three forms of MOUD increased from 4% to 9%. Interestingly, 83% of the U.S. population lives within 10 miles of a facility offering MOUD treatment, and 42% of the population have a treatment facility that offers all three forms of MOUD within a 10-mile radius. These differences between county and population-based measure can be explained by the correlation of densely populated areas with more facilities offering MOUD, which provides evidence that those who live in rural areas have much less access to treatment facilities offering MOUD.

CLICK TO READ THE ARTICLE

Resources



NJ MAT Centers of Excellence Integrating Medications for Addiction Treatment (MAT) into Office-Based Addiction Treatment: An Evidence-Based Manual for Primary Care and Specialty Practices Manual (First Edition)!

This manual will provide you with information about how to provide evidence-based care for patients with substance use disorders in the office-based setting, with a focus on opioid use disorder and alcohol use disorder, and provides recommendations for medical management. You will also find information on starting up an office-based treatment practice and integrating SUD care as part of your general medical practice. If you have any questions or comments on this manual, please contact us at the Northern NJ MAT Center of Excellence at coe@njms.rutgers.edu or the Southern NJ MAT Center of Excellence at southernnjcoe@rowan.edu

CLICK TO DOWNLOAD & SHARE THE MANUAL

Resources (cont.)


Buprenorphine Micro-Induction Patient Health Communication

This resource provides a protocol for buprenorphine micro-induction in the outpatient setting. MAT providers may often find themselves drawing out the micro-induction process for patients on paper, and we are pleased to share a visual leaflet written by Cooper University Health Care and Southern NJ MAT Center of Excellence physician leaders Rachel Haroz, MD, FAACT; Christopher Milburn, MD; and Kaitlan Baston, MD, DFASAM.

Please share the resource with interested patients!

To request the leaflet in varying size iterations, please contact the designer Patricia Fortunato at fortunato-patricia@cooperhealth.edu

CLICK TO DOWNLOAD & SHARE THE LEAFLET





National Institute on Drug Abuse Medication Infographic

Explore different types of medications prescribed for opioid overdose, withdrawal, and addiction that are safe, effective, and save lives.

CLICK TO DOWNLOAD & SHARE THE INFOGRAPHIC

24/7 MAT Provider Hotline: 844-HELP OUD (844-435-7683)
CLICK TO SHARE THE FLYER

Northern NJ MAT Center of Excellence Website & Email: bit.ly/mat-coe; coe@njms.rutgers.edu
Southern NJ MAT Center of Excellence Website & Email: snjmatcoe.org; southernnjcoe@rowan.edu

MEDICATION-ASSISTED TREATMENT
CENTERS OF EXCELLENCE